CoChat

Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer

Open access
Groot, Vincent P., Mosier, Stacy, Javed, Ammar A., Teinor, Jonathan A., Gemenetzis, Georgios, Ding, Ding, Haley, Lisa M., Yu, Jun, Burkhart, Richard A., Hasanain, Alina, Debeljak, Marija, Kamiyama, Hirohiko, Narang, Amol, Laheru, Daniel A., Zheng, Lei, Lin, Ming-Tseh, Gocke, Christopher D., Fishman, Elliot K., Hruban, Ralph H., Goggins, Michael G., Molenaar, I. Quintus, Cameron, John L., Weiss, Matthew J., Velculescu, Victor E., He, Jin, Wolfgang, Christopher L., Eshleman, James R. · 2019 · Clinical Cancer Research
Cited by 208

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Purpose: In research settings, circulating tumor DNA (ctDNA) shows promise as a tumor-specific biomarker for pancreatic ductal adenocarcinoma (PDAC). This study aims to perform analytical and clinical validation of a KRAS ctDNA assay in a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathology–certified clinical laboratory. Experimental Design: Digital-droplet PCR was used to detect the major PDAC-associated somatic KRAS mutations (G12D, G12V, G12R, and Q61H) in liquid biopsies. For clinical validation, 290 preoperative and longitudinal postoperative plasma samples were collected from 59 patients with PDAC. The utility of ctDNA status to predict PDAC recurrence during follow-up was assessed. Results: ctDNA was detected preoperatively in 29 (49%) patients and was an independent predictor of decreased recurrence-free survival (RFS) and overall survival (OS). Patients who had neoadjuvant chemotherapy were less likely to have preoperative ctDNA than were chemo-naïve patients (21% vs. 69%; P < 0.001). ctDNA levels dropped significantly after tumor resection. Persistence of ctDNA in the immediate postoperative period was associated with a high rate of recurrence and poor median RFS (5 months). ctDNA detected during follow-up predicted clinical recurrence [sensitivity 90% (95% confidence interval (CI), 74%–98%), specificity 88% (95% CI, 62%–98%)] with a median lead time of 84 days (interquartile range, 25–146). Detection of ctDNA during postpancreatectomy follow-up was associated with a median OS of 17 months, while median OS was not yet reached at 30 months for patients without ctDNA (P = 0.011). Conclusions: Measurement of KRAS ctDNA in a CLIA laboratory setting can be used to predict recurrence and survival in patients with PDAC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-0197

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 208

Metadata

Authors
Groot, V. P., Mosier, S., Javed, A. A., Teinor, J. A., Gemenetzis, G., Ding, D., Haley, L. M., Yu, J., Burkhart, R. A., Hasanain, A., Debeljak, M., Kamiyama, H., Narang, A., Laheru, D. A., Zheng, L., Lin, M.-T., Gocke, C. D., Fishman, E. K., Hruban, R. H., Goggins, M. G., Molenaar, I. Q., Cameron, J. L., Weiss, M. J., Velculescu, V. E., He, J., Wolfgang, C. L., & Eshleman, J. R.
Venue
Clinical Cancer Research
Published
2019-08-15
Volume
25
Issue
16
Pages
4973-4984
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2947818769
Cited by
208
References
12
FWCI
5.81
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-0197
The paper
Groot, V. P., Mosier, S., Javed, A. A., Teinor, J. A., Gemenetzis, G., Ding, D., Haley, L. M., Yu, J., Burkhart, R. A., Hasanain, A., Debeljak, M., Kamiyama, H., Narang, A., Laheru, D. A., Zheng, L., Lin, M.-T., Gocke, C. D., Fishman, E. K., Hruban, R. H., . . . Eshleman, J. R. (2019). Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-0197

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.